The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...